Prodigiosin Sensitizes Sensitive and Resistant Urothelial Carcinoma Cells to Cisplatin Treatment

Cisplatin-based treatment is the standard of care therapy for urothelial carcinomas. However, complex cisplatin resistance mechanisms limit the success of this approach. Both apoptosis and autophagy have been shown to contribute to this resistance. Prodigiosin, a secondary metabolite from various ba...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Molecules
Main Authors: Berning, Lena, Schlütermann, David, Friedrich, Annabelle, Berleth, Niklas, Sun, Yadong, Wu, Wenxian, Mendiburo, María José, Deitersen, Jana, Brass, Hannah U. C., Skowron, Margaretha A., Hoffmann, Michèle J., Niegisch, Günter, Pietruszka, Jörg, Stork, Björn
Format: Artigo
Jezik:Inglês
Izdano: MDPI 2021
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7957586/
https://ncbi.nlm.nih.gov/pubmed/33673611
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/molecules26051294
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki